

UK NEQAS FMH Update

Katy Veale

UK NEQAS (BTLP)

20/11/18

UK NEQAS Update

- **Katy**
 - Scheme redesign
 - Case study 1 – EQA sample
- **Rob**
 - Case study 2 – Patient sample
 - Flow Cytometry screening

Scheme redesign

- Live May 2018 (1803F)
- Registrations
 - New types
 - De-registered non-FMH users
- Refreshed
 - Data entry webpage
 - Report
- Feedback very welcome

Case study 1 - EQA


1804F P1 – 3mL




1804F P1 – 1mL

- Sources of error
 - User error?
 - Added cord material?
 - Incorrectly interpreted D type?
- **Next steps**
 - **Repeat FC testing**
 - **Repeat D typing**
 - **Examined plots**


Flow Cytometry




Normal FC report - 12mL



1804F P1




Repeat D typing






HELP!!!!

- Matt Hazell @ RCI
 - Likely D weak or variant
- Lynne Porter @ WBS
 - Likely D weak or variant, anti-HbF result 3.7mL
- **Shane Grimsley @ IBGRL**
 - **13/17 antisera showed normal reactions, likely D variant, not weak**
 - **BRAD3 “ever so slightly weaker than the control”**

Quantification results



Gating changed



BRAD3 Survey results

- 8/16 noticed unusual plots
 - 3 noticed but did not adjust (0.9, 2.6, 2.9mL)
- **12/16 had a back up plan**
 - **9 use anti-HbF / acid elution / refer the sample**
 - **2 repeat**
 - **1 match to controls**

Genotyping results

DVII

3,600 – 8,398 antigen sites
(Common = 10,000 – 33,000)

Learning points

- Look at your plots
- Modification of gates – trained staff only
- Have a back up plan
- Risks of not noticing / acting on unusual plots
- **Clearance rate may be different – binding sites**